大唐药业(836433) - 2023 Q4 - 年度业绩

Financial Performance - The company's operating revenue for 2023 reached ¥188,252,662.38, representing a year-on-year increase of 19.39%[4] - Net profit attributable to shareholders decreased by 48.61% to ¥7,644,018.38, while the net profit after deducting non-recurring gains and losses fell by 56.46% to ¥815,857.82[4] - Basic earnings per share dropped by 40% to ¥0.03, reflecting the decline in net profit[5] Assets and Equity - Total assets at the end of the reporting period amounted to ¥739,931,642.46, an increase of 14.51% compared to the beginning of the period[5] - Shareholders' equity attributable to the company increased by 1.12% to ¥488,047,942.98, with net assets per share rising by 2.16% to ¥1.89[5] Factors Affecting Profit - The decline in net profit was primarily due to reduced government subsidies, increased marketing expenses, and lower investment income from bank financial products[6] Market Expansion - The company expanded its market presence by enhancing sales channels, particularly in third-party and grassroots medical sales, contributing to revenue growth[6] Project Transition and Expenses - The company is currently transitioning its health technology industrial park project, leading to increased depreciation expenses[6] Financial Data Disclaimer - Investors are advised to note that the financial data presented is preliminary and unaudited, with final figures to be disclosed in the annual report[7] - The company emphasizes the importance of monitoring investment risks associated with the preliminary financial data[7]